Department of Urology & Urological Oncology, Division of Surgery, Hannover Medical School, Hannover, Germany.
Expert Rev Clin Pharmacol. 2013 May;6(3):323-32. doi: 10.1586/ecp.13.16.
To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic hyperplasia and symptoms of female sexual dysfunction (including arousal and orgasmic disorders), can be therapeutically approached by influencing the function of the smooth musculature of the respective tissues. The use of isoenzyme-selective phosphodiesterase (PDE) inhibitors is considered a great opportunity to treat various diseases of the human urogenital tract. PDE inhibitors, in particular the PDE5 (cyclic GMP PDE) inhibitors avanafil, lodenafil, sildenafil, tadalafil, udenafil and vardenafil, are regarded as efficacious, having a fast onset of drug action and an improved effect-to-adverse event ratio, combining a high response rate with the advantage of an on-demand intake. The purpose of this review is to summarize recent as well as potential future indications, namely, erectile dysfunction, Peyronie's disease, overactive bladder, urinary stone disease, lower urinary tract symptomatology secondary to benign prostatic hyperplasia and premature ejaculation, for the use of PDE inhibitors in clinical urology.
迄今为止，男性和女性下尿路和生殖器的良性疾病，如勃起功能障碍、膀胱过度活动症、良性前列腺增生引起的下尿路症状和女性性功能障碍（包括性欲和性高潮障碍）等，可通过影响相应组织平滑肌的功能进行治疗。使用同工酶选择性磷酸二酯酶（PDE）抑制剂被认为是治疗人类泌尿生殖道各种疾病的一个重要机会。PDE 抑制剂，特别是 PDE5（环鸟苷酸 PDE）抑制剂阿伐那非、洛地那非、西地那非、他达拉非、乌地那非和伐地那非，被认为是有效的，具有快速的药物作用起始和改善的疗效-不良反应比，将高反应率与按需摄入的优势相结合。本综述的目的是总结 PDE 抑制剂在临床泌尿外科中的近期和潜在的未来适应证，即勃起功能障碍、佩罗尼病、膀胱过度活动症、尿石症、良性前列腺增生引起的下尿路症状和早泄。
